A N-terminal specific polysarcosine-interferon conjugate (PSar-IFN) showed significantly more potency in inhibiting tumor growth, and elicited considerably less anti-IFN antibodies in mouse than its PEGylated counterpart (Hu et al., 2018). The gene discussed is IFNA1; the disease is neoplasm.